Enhancing Cancer Drug Effectiveness with Nitric Oxide Inhibition
Author Information
Author(s): SA Butler, PJ Wood, S Cole, C Williams, GE Adams, IJ Stratford
Primary Institution: Medical Research Council, Harwell, Oxon OX11 ORD, UK
Hypothesis
Inhibition of nitric oxide synthase activity may enhance the effectiveness of bioreductive drugs in treating tumors by increasing hypoxia.
Conclusion
Combining the nitric oxide synthase inhibitor nitro-L-arginine with the bioreductive drug RB6145 significantly increases anti-tumor activity in murine tumors.
Supporting Evidence
- Combining nitro-L-arginine with RB6145 reduced survival of KHT tumor cells by 3-4 logs.
- RB6145 or nitro-L-arginine alone caused no more than 20% cell kill.
- The tumor response to the drug combination was dependent on tumor size.
- Histological examination showed increased necrosis in tumors treated with the drug combination.
Takeaway
This study found that a special drug can work better against tumors when another drug is used to block a certain chemical in the body, making the tumors less healthy.
Methodology
Mice with tumors were treated with RB6145 and nitro-L-arginine, and tumor cell survival was assessed using clonogenic assays.
Limitations
The study was conducted in murine models, which may not fully represent human responses.
Participant Demographics
Male and female C3H/He mice, aged 8-12 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website